Tag Archive for: end stage liver disease

Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001

/in

EMERALD Study will investigate safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis Edinburgh and London, UK, 27 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease today announces it has received approval from the U.K. Medicines and Healthcare […]

Read more

Resolution Therapeutics to Host Virtual Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

/in

Highlighting Clinical Data and Discovery Platform Following Presentations at EASL Congress 2024 Edinburgh and London, UK, 13 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease, today announces that it will host a virtual R&D webinar on Friday 28th June 2024 at 12.30 BST / 7.30 […]

Read more

Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024

/in

MATCH Phase 2 data underscores significant potential of macrophage cell therapy treatment for advanced liver cirrhosis Resolution Therapeutics presents novel discovery platform for engineered macrophage cell therapy to enhance therapeutic efficacy Edinburgh and London, UK, 5 June 2024 – Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver […]

Read more
© Optimum Strategic Communications.